Related Experiment Video
Updated: Dec 29, 2025

06:52
Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres
Published on: July 22, 2020
6.9K
Combined burden and functional impact tests for cancer driver discovery using DriverPower
Shimin Shuai1,2, , Steven Gallinger3,4
1Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada, M5S 1A8. shimin.shuai@mail.utoronto.ca.
Nature Communications
|February 7, 2020
Summary
DriverPower, a new software package, identifies cancer driver mutations using mutational burden and functional impact. It accurately detects both coding and non-coding mutations across diverse cancer types.
Area of Science:
- Genomics
- Bioinformatics
- Cancer Research
Background:
- Cancer genome sequencing aims to discover driver mutations.
- The ICGC/TCGA Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium analyzed 2658 cancer genomes.
- Identifying driver mutations in both coding and non-coding regions is crucial.
Purpose of the Study:
- To introduce DriverPower, a novel software package for identifying driver mutations.
- To leverage mutational burden and functional impact evidence for enhanced driver discovery.
- To analyze whole genome sequencing data from the PCAWG project.
Main Methods:
- DriverPower utilizes 1373 genomic features to model background mutation rates.
- The software incorporates functional impact scores to improve driver identification accuracy.
- A background mutation model explains up to 93% of regional mutation rate variance.
Main Results:
- DriverPower identified 217 coding and 95 non-coding driver candidates in 2583 PCAWG cancer genomes.
- The software demonstrated superior performance compared to six other methods.
- DriverPower achieved the highest F1 score for both coding and non-coding driver discovery.
Conclusions:
- DriverPower is an effective computational framework for identifying cancer driver mutations.
- The software enhances driver discovery by integrating mutational burden and functional impact.
- This approach improves the accuracy of identifying both coding and non-coding drivers.
Related Concept Videos
Mutagenicity and Carcinogenicity
1.8K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.8K
Cancer Survival Analysis
600
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
600
Cancer-Critical Genes II: Tumor Suppressor Genes
9.3K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.3K

